InMed Pharmaceuticals Inc.

INM

CA4576376012

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 24/05/2024 BST			5-day change	1st Jan Change
0.3033 ^USD	-3.71%		+2.85%	-27.09%

05-14	Earnings Flash (INM) INMED PHARMACEUTICALS Posts Q3 Revenue $1.2M	MT
05-14	InMed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI

Martin Bott Steps Down from the Board of Directors of InMed Pharmaceuticals Inc

September 03, 2019 at 12:57 pm

InMed Pharmaceuticals Inc. announced that, Martin Bott has decided to resign as a Director of the Company, effective August 31, 2019, due to additional professional and personal responsibilities.

Latest news about InMed Pharmaceuticals Inc.

Earnings Flash (INM) INMED PHARMACEUTICALS Posts Q3 Revenue $1.2M	05-14	MT
InMed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	05-14	CI
InMed Pharmaceuticals Inc. Appoints David G. Morgan to its Scientific Advisory Board	04-17	CI
InMed Pharmaceuticals Inc. Announces Additional Preclinical Data Demonstrating INM-901'S Positive Pharmacological Effects in the Potential Treatment of Alzheimer's Disease	04-04	CI
InMed Pharmaceuticals Inc. Provides Update on Pharmaceutical Development Programs	02-13	CI
InMed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-13	CI
InMed Pharmaceuticals Inc. Announces Chief Financial Officer Changes, Effective February 20, 2024	02-09	CI
InMed Pharmaceuticals Inc. Announces Executive Changes, Effective February 20, 2024	02-09	CI
Transcript : InMed Pharmaceuticals Inc. - Special Call	01-25
Transcript : InMed Pharmaceuticals Inc. - Shareholder/Analyst Call	12-19
Inmed Pharmaceuticals Inc. Announces the Launch of Inm-089	11-29	CI
InMed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-14	CI
InMed Pharmaceuticals Inc. Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch 2023	11-02	CI
InMed Pharmaceuticals Inc. announced that it has received CAD 5.000002 million in funding	25/10/23	CI
Inmed Pharmaceuticals Inc. Selects A Lead Alzheimer's Disease Drug Candidate, Named INM-901	24/10/23	CI
InMed Pharmaceuticals Inc. announced that it expects to receive CAD 5.000002 million in funding	23/10/23	CI
InMed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	29/09/23	CI
InMed Pharmaceuticals Gets Non-Compliance Notice From Nasdaq	25/09/23	MT
Transcript : InMed Pharmaceuticals Inc. - Special Call	25/07/23
InMed Pharmaceuticals Inc. Announces Safety and Efficacy Results from its Phase 2 Clinical Trial, Called 755-201-EB	22/06/23	CI
InMed Pharmaceuticals Inc.'s Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting	01/06/23	CI
Transcript : InMed Pharmaceuticals Inc. - Special Call	31/05/23
InMed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	15/05/23	CI
InMed Pharmaceuticals Completes Patient Enrollment for Phase 2 Trial of INM-755 in Epidermolysis Bullosa	28/03/23	MT
InMed Pharmaceuticals Inc. Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating Inm-755 Cannabinol Cream for Epidermolysis Bullosa	28/03/23	CI

Chart InMed Pharmaceuticals Inc.

Duration

Period

More charts

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.

Sector

Biotechnology & Medical Research

Calendar

19/09/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INMED PHARMACEUTICALS INC.	-27.09%	1.91M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	116B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.89B
ARGENX SE	-1.69%	21.58B
GENMAB A/S	-10.60%	18.96B
WUXI APPTEC CO., LTD.	-41.25%	16.96B
BEIGENE, LTD.	-15.33%	16.33B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.14B
SAREPTA THERAPEUTICS, INC.	+28.03%	12.02B

Bio Therapeutic Drugs

InMed Pharmaceuticals Inc.

Equities

INM

CA4576376012

Biotechnology & Medical Research

Martin Bott Steps Down from the Board of Directors of InMed Pharmaceuticals Inc

Latest news about InMed Pharmaceuticals Inc.

Chart InMed Pharmaceuticals Inc.

Company Profile

Income Statement Evolution

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs